Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection
Abstract
Sorafenib is acknowledged as the standard therapy for advanced hepatocellular carcinoma (HCC) but in the clinical practice the treatment of these patients is extremely complex and needs to be personalized. New evidence suggests that surgical resection-based multimodal treatments may improve outcome in these patients. There is no strong evidence supporting the ability of sorafenib in downstage HCC before surgery. We presented a case of a...
Paper Details
Title
Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection
Published Date
Mar 1, 2020
Journal
Volume
17
Issue
2
Pages
83 - 87
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History